Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Voclosporin in Lupus Nephritis: NCT07611214 Clinical Landscape Report 2026
9 min read
Voclosporin in Lupus Nephritis: NCT07611214 Clinical Landscape Report 2026
16 September 2026
NCT07611214 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ipilimumab in Advanced Renal Cell Carcinoma: NCT07611825 Clinical Landscape Report 2026
9 min read
Ipilimumab in Advanced Renal Cell Carcinoma: NCT07611825 Clinical Landscape Report 2026
16 September 2026
NCT07611825 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
ALK.CAR-T cells(University of Turin/Boston Children) in Relapse multiple myeloma: NCT07611149 Clinical Landscape Report 2026
9 min read
ALK.CAR-T cells(University of Turin/Boston Children) in Relapse multiple myeloma: NCT07611149 Clinical Landscape Report 2026
16 September 2026
NCT07611149 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
INV-8989 in Locally Advanced Malignant Solid Neoplasm: NCT07610798 Clinical Landscape Report 2026
9 min read
INV-8989 in Locally Advanced Malignant Solid Neoplasm: NCT07610798 Clinical Landscape Report 2026
16 September 2026
NCT07610798 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
Pembrolizumab in Solid tumor: NCT07610941 Clinical Landscape Report 2026
9 min read
Pembrolizumab in Solid tumor: NCT07610941 Clinical Landscape Report 2026
16 September 2026
NCT07610941 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07610525 Clinical Landscape Report 2026
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07610525 Clinical Landscape Report 2026
16 September 2026
NCT07610525 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Bmab1800 (Biocon Biologics UK Ltd.) in Mucosal Melanoma: PACTR202605570676346 Clinical Landscape Report 2026
9 min read
Bmab1800 (Biocon Biologics UK Ltd.) in Mucosal Melanoma: PACTR202605570676346 Clinical Landscape Report 2026
16 September 2026
PACTR202605570676346 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
CAIX(Zonsen Peplib Biotech) in Neoplasms: PACTR202605495669702 Clinical Landscape Report 2026
9 min read
CAIX(Zonsen Peplib Biotech) in Neoplasms: PACTR202605495669702 Clinical Landscape Report 2026
16 September 2026
PACTR202605495669702 clinical landscape for Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
FXS0683 in Acute Myeloid Leukemia: NCT07616089 Clinical Landscape Report 2026
9 min read
FXS0683 in Acute Myeloid Leukemia: NCT07616089 Clinical Landscape Report 2026
16 September 2026
NCT07616089 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Mobocertinib Succinate in Metastatic Clear Cell Renal Cell Carcinoma: NCT07615348 Clinical Landscape Report 2026
9 min read
Mobocertinib Succinate in Metastatic Clear Cell Renal Cell Carcinoma: NCT07615348 Clinical Landscape Report 2026
16 September 2026
NCT07615348 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
Read →
Silodosin in Multiple Sclerosis: NCT07614321 Clinical Landscape Report 2026
9 min read
Silodosin in Multiple Sclerosis: NCT07614321 Clinical Landscape Report 2026
16 September 2026
NCT07614321 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
GT801 in Idiopathic Inflammatory Myopathies: NCT07614191 Clinical Landscape Report 2026
9 min read
GT801 in Idiopathic Inflammatory Myopathies: NCT07614191 Clinical Landscape Report 2026
16 September 2026
NCT07614191 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
Read →